Table 2.
Incidence rate (per 1,000 person-years) of left ventricular ejection fraction (LVEF) decline among soft tissue sarcoma patients with cardiac imaging at follow-up in Western Denmark (regional cohort), 1997–2011
| Characteristics | LVEF decline
|
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Follow-up dataa
|
Baseline and follow-up datab
|
|||||||||
| Total N | Number of events | % | Person-years | Incidence rate (95% confidence interval) | Total N | Number of events | % | Person- years | Incidence rate (95% confidence interval) | |
| Total | 100 | 5 | 5.0 | 298.4 | 16.8 (7.0–40.3) | 75 | 19 | 25.3 | 175.3 | 108 (69–170) |
| Age, years | ||||||||||
| <40 | 26 | 0 | 0.0 | 99.4 | – | 18 | 2 | 11.1 | 63.8 | 31 (7.8–125) |
| 40–59 | 44 | 2 | 4.5 | 132.2 | 15.1 (3.8–60.5) | 33 | 9 | 27.3 | 84.3 | 107 (56–205) |
| 60–79 | 30 | 3 | 10.0 | 66.9 | 44.9 (14.5–139) | 24 | 8 | 33.3 | 27.2 | 294 (147–588) |
| Sex | ||||||||||
| Female | 43 | 2 | 4.7 | 144.8 | 13.8 (3.5–55.2) | 31 | 8 | 25.8 | 76.7 | 104 (52–208) |
| Male | 57 | 3 | 5.3 | 153.6 | 19.5 (6.3–61) | 44 | 11 | 25.0 | 98.6 | 112 (62–201) |
| Chemotherapy | ||||||||||
| Doxorubicin | 86 | 4 | 4.7 | 252.6 | 15.8 (5.9–42.2) | 66 | 16 | 24.2 | 148 | 108 (66–177) |
| Epirubicin | 1 | 1 | 100 | 0.3 | 3204 (451–22,746) | 1 | 1 | 100 | 0.3 | 3204 (451–22,745) |
| Other | 7 | 0 | 0.0 | 26.7 | – | 4 | 0 | 0 | 20.3 | – |
| Vincristine | 1 | 0 | 0.0 | 3.7 | – | 1 | 1 | 100 | 2.4 | 421 (59–2,990) |
| Ifosfamide | 5 | 0 | 0.0 | 15.1 | – | 3 | 1 | 33.3 | 4.3 | 231 (33–1,642) |
| Stage at diagnosis | ||||||||||
| IA | 1 | 0 | 0 | 3.1 | – | 1 | 0 | 0 | 3.1 | – |
| IB | 3 | 0 | 0 | 8.1 | – | 3 | 1 | 33.3 | 6.2 | 161.6 (22.8–1,147.4) |
| IIA | 3 | 1 | 33.3 | 12.5 | 79.6 (11.3–567.2) | 3 | 1 | 33.3 | 12.5 | 79.9 (11.3–567.2) |
| IIB | 4 | 1 | 25.0 | 13.6 | 73.7 (10.4–523.1) | 2 | 1 | 50.0 | 6.5 | 154.6 (21.8–1,097.3) |
| III | 25 | 1 | 4.0 | 75.6 | 13.2 (1.9–93.6) | 20 | 4 | 20.0 | 36.3 | 110.3 (41.4–293.9) |
| IV | 12 | 1 | 8.3 | 18.6 | 53.9 (7.6–382.6) | 9 | 3 | 33.3 | 6.9 | 437.1 (141.0–1,355.2) |
| Unknown | 52 | 1 | 1.9 | 166.8 | 6.0 (0.8–42.6) | 37 | 9 | 24.3 | 103.9 | 86.6 (45.1–166.5) |
Notes:
a
LVEF decline: follow-up LVEF below lower limit of normal (or <40%).
b
LVEF decline: absolute drop from baseline to follow-up of 10% or greater.
Abbreviations: –, not available; LVEF, left ventricular ejection fraction.